Researchers have discovered that targeting PD-L1 recycling in myeloid cells enhances T-cell activation and boosts the effects ...
European Commission approves Merck’s Keytruda as part of a treatment regimen for adults with resectable LA-HNSCC expressing PD-L1: Rahway, New Jersey Thursday, October 30, 2025, ...
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...
News Medical on MSN
Boosting First Responder Cells May Aid Cancer Therapy
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...
2d
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer
CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...
Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice ...
Merck & Eisai announce Welireg plus Lenvima meets primary endpoint of PFS in certain previously treated patients with advanced RCC: Rahway, New Jersey Wednesday, October 29, 2025, ...
Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, British Columbia, Saskatchewan, Nova Scotia, Newfoundland and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback